Connecting You to Tomorrow's Biotechnology Innovations
For the first time ever, Mount Sinai researchers have identified a protein as a marker that can indicate whether a cancer patient will develop a reoccurrence of lethal, metastatic cancer, according to a clinical study published in Breast Cancer Research in October. The researchers found that when cells from a breast cancer patient’s original tumor metastasized into […]
Women undergoing mastectomy for breast cancer experience improved postsurgical pain relief and reduced opioid consumption when given a pectoralis nerve plane (PECS) block prior to surgery, suggests research presented at the ANESTHESIOLOGY® 2018 annual meeting. The PECS block is a newer regional anesthesia technique that works by injecting long-acting anesthetics, guided by ultrasound, to numb the front […]
A new study by University of Kentucky Markey Cancer Center researchers suggests that targeting a protein known as collagen XIII could be key for suppressing breast cancer metastasis. Breast cancers begin in the epithelial cells, which are the cells that line organs and tissues in the body. Generally, most epithelial cells will die after detaching from their […]
Approximately 10-20 percent of diagnosed breast cancers are found to be triple-negative, meaning the breast cancer cells test negative for estrogen and progesterone receptors as well as HER2 receptors, genes that can play a role in the development of breast cancer. Triple-negative breast cancer can be more aggressive and difficult to treat as the cancer […]
Phase I clinical trial will combine standard chemotherapy with cirmtuzumab, a drug that has shown promise against a variety of cancer types Researchers at University of California San Diego School of Medicine have launched a phase Ib clinical trial to assess the safety and tolerability of cirmtuzumab, in combination with standard chemotherapy, to treat metastatic or […]
The Cancer Center of Kansas (CCK) has been added as a new clinical trial site and will be part of an ongoing, multicenter, Phase IIa study of Bria-IMT™ (listed in ClinicalTrials.gov as NCT03066947) in advanced breast cancer, as well as the rollover combination study of BriaCell Therapeutic’s Bria-IMT™ with pembrolizumab or ipilimumab (listed in ClinicalTrials.gov […]
A new study from the Stanford Cancer Institute finds that young women who are treated with chemotherapy for breast cancer but have residual tumor in either the breast or lymph nodes have higher chances of recurrence compared to those with no evidence of any residual invasive tumor (pathologic complete response). The findings were published in […]
A new multi-institutional clinical trial compared outcomes of women with multiple ipsilateral breast cancer, or more than one site of disease in the same breast, who underwent breast-conserving surgery, with outcomes of those who converted to mastectomy. Out of 198 eligible women in the trial, 184 (92.9%) successfully completed breast-conserving surgery, 134 of those with […]